MMIT (Managed Markets Insight & Technology)

Dive into the latest insights from our top experts and stay updated with the most recent developments in market access.

New in today's Radar on Medicare Advantage: https://hubs.ly/Q02Z4twF0 MA gets an ally in Dr. Oz, the odds of an MA rebate overhaul in a second Trump administration, the mid-AEP marketing changes raising brokers' eyebrows, and more top stories.

Integrating real-world datasets with payer policy and restriction data reveals the full scope of the patient journey. https://ow.ly/IRgL50U8huJ In Drug Channels Institute, an HMP Global Company, MMIT’s Kala Bala and Dinesh Kabaleeswaran discuss the evolution of market access and what pharma can accomplish with AI and predictive analytics. #MarketAccess #PharmaInnovation #PredictiveAnalytics #PatientJourney

https://ow.ly/CKG750UapAa Discover how leading pharmaceutical companies leverage MMIT's powerful Analytics platform to gain seamless access to comprehensive formulary information, medical policies, and restriction details. Download our case studies to see how our user-friendly technology drives industry success at the link in this post.

Following a successful defense of its Pavblu (aflibercept-ayyh), Amgen recently launched the drug at risk. https://hubs.ly/Q02YxkML0 Pavblu is one of five FDA-approved biosimilars of Regeneron Pharmaceuticals, Inc.’s best-selling Eylea (aflibercept), but patent infringement lawsuits by the drugmaker have kept those competitors off the U.S. market — until now. The agent is entering an increasingly crowded therapeutic class, but it’s one that’s also costly for payers, which may be seeking some savings. Is its price good enough to pull market share? Industry experts weigh in on its prospects in the latest issue of Radar on Specialty Pharmacy from AIS Health. https://hubs.ly/Q02Yxv0K0

Making sense of access data can be a time and resource-consuming challenge. Learn how MMIT can help your team simplify the process. https://ow.ly/VR8r50TQi2Z

Several state Medicaid programs continue to restrict access to hepatitis C medications that could cure beneficiaries, reduce health inequities and decrease health care costs. https://hubs.ly/Q02Yxt4M0 That's according to a JAMA Network Open study authored by Centers for Disease Control and Prevention (CDC) employees. Nathan W. Furukawa, M.D., the lead author, tells AIS Health's Radar on Drug Benefits that while the restrictions have eased over time, more needs to be done to help patients and eliminate a disease that has multiple curative treatments. The authors noted that since the FDA first approved oral direct-acting antivirals (DAAs) for hepatitis C in 2013, the medications have proven to be associated with cure rates of greater than 95% within 8 to 12 weeks. However, usage of the medications has been less than expected in part because payers are wary of their high costs. Subscribe to read the full article today. https://hubs.ly/Q02Yx4690

Pharma companies should evaluate payers using multiple datasets to fully understand how they impact patient access. https://ow.ly/csyg50U9bcE Click the link in this post to find out the top eight questions MMIT’s pharma clients are addressing with our integrated claims and coverage data.

Tracking payer coverage changes in real time is essential for driving utilization. https://ow.ly/xcL250U9zcx In this case study, learn how one pharma company used MMIT's data to target payer accounts and identify pull-through opportunities, ultimately increasing their brands' prescriptions. Download the case study now. #MarketAccess #PayerInsights #MarketAccessStrategy #PharmaManufacturer

Now available in the November issue of Radar on Specialty Pharmacy: https://hubs.ly/Q02YgfYM0 Amgen's odds of pulling market share from Eylea, how Eli Lilly and Company's new Alzheimer's drug could impact rebate negotiations, why pharma's support will be key to the FDA's prospects under a second Trump administration, and more top stories.